Literature DB >> 7524438

Band heterotopia: correlation of outcome with magnetic resonance imaging parameters.

A J Barkovich1, R Guerrini, G Battaglia, G Kalifa, T N'Guyen, A Parmeggiani, M Santucci, P Giovanardi-Rossi, T Granata, L D'Incerti.   

Abstract

The "band heterotopia" or "double cortex" is a brain anomaly that is presumed to result from a premature arrest of neuronal migration. Patients with this anomaly are reported to have a variable clinical course that has been, heretofore, unpredictable. The clinical records and magnetic resonance (MR) imaging studies of 27 patients with band heterotopia were retrospectively reviewed in an attempt to determine whether imaging findings are useful in predicting clinical outcome of affected patients. Statistical analyses revealed the following correlations: (1) severity of T2 prolongation in the brain with motor delay (p = 0.03); (2) degree of ventricular enlargement with the age of seizure onset (p = 0.04), and with development and intelligence (p = 0.04); (3) severity of pachygyria with the age of seizure onset (p = 0.01), seizure type (p = 0.03), and an abnormal neurologic examination (p = 0.002); (4) parietal involvement with delayed speech development (p = 0.05); (5) occipital involvement with age of seizure onset (p = 0.006); (6) age of seizure onset with development and intelligence (p = 0.03) and with an abnormal neurologic examination (p = 0.04); and (7) severity of the pachygyria and thickness of band with development of symptomatic generalized epilepsy (p = 0.002 and p = 0.02, respectively) and Lennox-Gastaut syndrome (p = 0.002 and p = 0.01, respectively).

Entities:  

Mesh:

Year:  1994        PMID: 7524438     DOI: 10.1002/ana.410360409

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  37 in total

1.  Syndromes of bilateral symmetrical polymicrogyria.

Authors:  A J Barkovich; R Hevner; R Guerrini
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

2.  Dominant X linked subcortical laminar heterotopia and lissencephaly syndrome (XSCLH/LIS): evidence for the occurrence of mutation in males and mapping of a potential locus in Xq22.

Authors:  V des Portes; J M Pinard; D Smadja; J Motte; O Boespflüg-Tanguy; M L Moutard; I Desguerre; P Billuart; A Carrie; T Bienvenu; M C Vinet; L Bachner; C Beldjord; O Dulac; A Kahn; G Ponsot; J Chelly
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

3.  Sensorimotor organization in double cortex syndrome.

Authors:  Jeffrey D Jirsch; Neda Bernasconi; Flavio Villani; Paolo Vitali; Giuliano Avanzini; Andrea Bernasconi
Journal:  Hum Brain Mapp       Date:  2006-06       Impact factor: 5.038

Review 4.  Genetic malformations of cortical development.

Authors:  Renzo Guerrini; Carla Marini
Journal:  Exp Brain Res       Date:  2006-05-25       Impact factor: 1.972

Review 5.  Comprehensive genotype-phenotype correlation in lissencephaly.

Authors:  Ai Peng Tan; Wui Khean Chong; Kshitij Mankad
Journal:  Quant Imaging Med Surg       Date:  2018-08

Review 6.  Malformations of cortical development.

Authors:  Trudy Pang; Ramin Atefy; Volney Sheen
Journal:  Neurologist       Date:  2008-05       Impact factor: 1.398

Review 7.  Advances in neurology.

Authors:  C R Kennedy
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

Review 8.  Malformations of cortical development and epilepsy.

Authors:  A James Barkovich; William B Dobyns; Renzo Guerrini
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

9.  Visual Impairment Due to Lissencephaly.

Authors:  V E Marqués-Fernández; H Sánchez-Tocino; M T Escudero-Caro; R Cancho-Candela; M García-Zamora
Journal:  Neuroophthalmology       Date:  2016-07-21

10.  Dcx reexpression reduces subcortical band heterotopia and seizure threshold in an animal model of neuronal migration disorder.

Authors:  Jean-Bernard Manent; Yu Wang; Yoonjeung Chang; Murugan Paramasivam; Joseph J LoTurco
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.